Several contributing factors may explain the low efficacies obtained so far, including drug resistance, alternative triggers of angiogenesis, vessel co-option and the problem of identifying who will benefit from anti-VEGF therapy in breast cancer. The gene discussed is VEGFA; the disease is breast carcinoma.